Evidence map›Paper›PMID 36110850›Full record

ArticleFrontiers in immunology2022

Immune modulation as a consequence of SARS-CoV-2 infection.

Metin Yusuf Gelmez, Fatma Betul Oktelik, Ilhan Tahrali, Vuslat Yilmaz, Umut Can Kucuksezer, Nilgun Akdeniz, Esin Aktas Cetin, Murat Kose, Cigdem Cinar, Fatma Savran Oguz and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Metin Yusuf GelmezDepartment of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Fatma Betul OktelikDepartment of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Ilhan TahraliDepartment of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Vuslat YilmazDepartment of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Umut Can KucuksezerDepartment of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Nilgun AkdenizDepartment of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Esin Aktas CetinDepartment of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Murat KoseDepartment of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Cigdem CinarDepartment of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Fatma Savran OguzDepartment of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Sevgi BesisikDivision of Hematology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Kaya KoksalanLaboratory of Molecular Tuberculosis Epidemiology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Ozkan OzdemirGenome Studies Program, Institute of Health Sciences, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Turkey.
Naci SenkalDepartment of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Ahmet GulDivision of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Erdem TuzunDepartment of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Gunnur DenizDepartment of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Istanbul University · TRKent Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Erroneous immune responses in COVID-19 could have detrimental effects, which makes investigation of immune network underlying COVID-19 pathogenesis a requisite. This study aimed to investigate COVID-19 related alterations within the frame of innate and adaptive immunity. Thirty-four patients clinically diagnosed with mild, moderate and severe COVID-19 disease were enrolled in this study. Decreased ILC1 and increased ILC2 subsets were detected in mild and moderate patients compared to healthy controls. NK cell subsets and cytotoxic capacity of NK cells were decreased in severe patients. Moreover, CD3

Indexed as

COVID-19CD8-Positive T-LymphocytesCytokinesHumansImmunity, InnateImmunoglobulin AImmunoglobulin GInterleukin-10Interleukin-6Interleukin-8Killer Cells, NaturalSARS-CoV-2Tumor Necrosis Factor-alphaCytokinesImmunoglobulin AImmunoglobulin GInterleukin-10Interleukin-6Interleukin-8Tumor Necrosis Factor-alphaB cellsCOVID-19ILCsNK cellsSARS-CoV-2T cells

Identifiers

PMID36110850
PMCPMC9468265
OpenAlexW4293770062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.